Composition for preventing or treating hearing loss, containing atorvastatin as active ingredient
The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.
1. A method for preventing or treating sensorineural hearing loss in a diabetic human in need thereof, the method comprising administering a therapeutically effective amount of atorvastatin to the diabetic human, wherein the sensorineural hearing loss is diabetes-mediated hearing loss.
2. The method according to claim 1 , wherein the atorvastatin inhibits apoptosis of auditory cells, promotes AKT phosphorylation, or maintains ATP production.
3. The method according to claim 1 , wherein the atorvastatin inhibits insulin tolerance or glucose tolerance.
4. The method according to claim 1 , wherein the method comprises administering to the diabetic human a pharmaceutical composition containing the atorvastatin.
5. The method according to claim 4 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable additive.
6. The method according to claim 5 , wherein the pharmaceutically acceptable additive comprises at least one selected from the group consisting of an excipient, a binder, a slip modifier, a lubricant, a disintegrating agent, a sweetener, a flavor, and a mixture thereof.
7. The method according to claim 1 , wherein the method comprises administering to the diabetic human a tablet containing the atorvastatin.
8. The method according to claim 7 , wherein the tablet is coated.